Literature DB >> 2543647

Cells derived from sporadic and AIDS-related Kaposi's sarcoma reveal identical cytochemical and molecular properties in vitro.

S Werner1, P H Hofschneider, W K Roth.   

Abstract

We have established 40 cell cultures from biopsies of 5 patients with sporadic Kaposi's sarcoma (KS) and compared them with cell cultures derived from KS biopsies of AIDS patients. Immunocytochemical staining of sporadic KS cells revealed the same endothelial cell markers as those expressed on AIDS-KS cells, indicating that both types of KS might be of endothelial cell origin. In contrast to clinical features, in vitro growth properties showed no differences. KS cells of both types reveal a low degree of malignancy but can be distinguished from fibroblasts by a higher passage number in low serum concentrations and a more pronounced dependence on platelet-derived growth factor (PDGF). The DNA of 12 cell lines of both types of KS was negative for genomic equivalents of hepatitis B virus (HBV), cytomegalovirus (CMV) and, in the case of AIDS-KS, for human immunodeficiency virus (HIV). No rearrangements or amplifications of several oncogenes, often involved in human tumors, were detected. The expression of these oncogenes by sporadic and AIDS-KS cells, as analyzed by Northern blotting, was comparable to that of normal dermal fibroblasts from the same patients. Our results indicate that the 2 types of Kaposi's sarcoma possess identical cytochemical and molecular properties. They are probably weakly malignant neoplasms of endothelial cell origin, and paracrine growth stimulation appears to be important for their maintenance and progression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543647     DOI: 10.1002/ijc.2910430629

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  HIV-associated Kaposi's sarcoma: new developments in epidemiology and molecular pathology.

Authors:  W K Roth
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.

Authors:  S R Husain; P Gill; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

3.  Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells.

Authors:  Shou-Jiang Gao; Jian-Hong Deng; Fu-Chun Zhou
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  Expression of int-2 oncogene in Kaposi's sarcoma lesions.

Authors:  Y Q Huang; J J Li; D Moscatelli; C Basilico; A Nicolaides; W G Zhang; B J Poiesz; A E Friedman-Kien
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

5.  Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance.

Authors:  M Stürzl; W K Roth; N H Brockmeyer; C Zietz; B Speiser; P H Hofschneider
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

6.  Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities.

Authors:  S Werner; D S Duan; C de Vries; K G Peters; D E Johnson; L T Williams
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

7.  Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection.

Authors:  Myung-Shin Lee; Tiffany Jones; Dae-Yong Song; Jae-Hyuk Jang; Jae U Jung; Shou-Jiang Gao
Journal:  PLoS Pathog       Date:  2014-09-25       Impact factor: 6.823

8.  Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis.

Authors:  F Bussolino; M Arese; G Montrucchio; L Barra; L Primo; R Benelli; F Sanavio; M Aglietta; D Ghigo; M R Rola-Pleszczynski
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.